Ocrevus Home Infusion: A Growing Option Surrounded by Debate

Few biologic medications have generated as much discussion around home infusion as Ocrevus (ocrelizumab). While insurance companies increasingly push for home administration to cut costs, the medication’s manufacturer initially resisted the trend, and neurologists remain divided on whether home is the right setting. For patients with multiple sclerosis navigating this landscape, the reality is more nuanced than either side suggests.

The Controversy Around Home Ocrevus

When Ocrevus launched in 2017 as a breakthrough treatment for both relapsing and primary progressive MS, it was administered exclusively in clinical settings. FDA labeling recommends administration in a setting with access to appropriate medical support to manage severe infusion reactions, though it does not explicitly prohibit home infusion.

Genentech, the manufacturer, initially took a firm stance against home administration. The company cited the risk of infusion-related reactions — which occur in 34 to 40% of patients with their first dose — and the need for adequate monitoring infrastructure. This position put Genentech at odds with a growing number of insurers and pharmacy benefit managers who saw home infusion as a way to reduce costs, since hospital outpatient infusion charges for Ocrevus can be substantially higher.

The tension came to a head during the COVID-19 pandemic, when patients who were immunosuppressed by Ocrevus faced heightened infection risk in clinical settings. Demand for home infusion surged, and the practical landscape shifted rapidly.

Where Things Stand Now

The landscape has evolved considerably. While Genentech has softened its position, the company still recommends that the initial doses be given in a supervised medical setting. Most insurers, prescribers, and home infusion pharmacies have converged on a set of practical standards:

• First two half-doses (the split initial dose at weeks 0 and 2) should be administered in a clinic or infusion center
• At least one full maintenance dose (600 mg) should be tolerated in a clinical setting before transitioning home
• Patients must have no history of severe infusion reactions with ocrelizumab
• A physician order specifically authorizing home infusion must be on file

Some insurers are more aggressive, requiring only the split first dose in-clinic before approving home infusion. Others remain conservative and require two or more full maintenance infusions under clinical supervision. Patients should verify their specific plan’s requirements early in the process.

The First-Dose-in-Clinic Requirement

The first Ocrevus dose is split into two 300 mg infusions given two weeks apart. This approach reduces reaction severity, but it also means the period of highest risk is concentrated in these early treatments. According to National MS Society resources, the majority of infusion-related reactions occur with the first infusion, and their frequency decreases with subsequent doses.

After the initial doses, full 600 mg maintenance infusions are given every six months. With the FDA-approved shorter infusion option, experienced patients may receive maintenance doses in approximately 2 hours rather than the original 3.5-hour protocol. This shorter infusion time has made home administration more practical for both patients and nurses.

What Home Ocrevus Infusion Looks Like

A home Ocrevus infusion is a longer commitment than many other home biologic infusions. Here is what a typical appointment involves:

1. Premedication (30 minutes before): The nurse administers methylprednisolone (a corticosteroid) intravenously, along with acetaminophen and an antihistamine such as diphenhydramine, to reduce reaction risk
2. Infusion (2 to 3.5 hours): The Ocrevus infusion runs at a controlled rate, with the nurse monitoring vitals at regular intervals
3. Post-infusion observation (at least 1 hour): The nurse remains to monitor for delayed reactions

Total time from nurse arrival to departure is typically 4 to 5.5 hours. The nurse carries emergency medications including epinephrine, additional corticosteroids, and bronchodilators. Reliable phone service and proximity to an emergency department are practical requirements for home administration.

One logistical detail patients sometimes overlook: Ocrevus requires refrigerated storage and must be diluted before infusion. The home infusion pharmacy handles preparation and cold-chain shipping, but patients need adequate refrigerator space to store the medication until the infusion appointment.

The Patient Perspective

For people living with MS — a condition that can cause fatigue, mobility challenges, and heat sensitivity — the value of avoiding travel to an infusion center can be significant. Patients who have successfully transitioned to home Ocrevus infusions frequently cite several benefits:

• Eliminating a full day of travel and clinic waiting time, especially for those in rural areas
• Resting in their own environment during and after infusion, which matters given the fatigue many patients experience post-treatment
• Reduced exposure to infections in immunocompromised patients
• Greater scheduling flexibility compared to busy infusion centers

However, some patients report preferring the clinical setting, particularly those who value the reassurance of having a full medical team immediately available, or who appreciate the social connection of an infusion center. Patients comparing Ocrevus and Kesimpta may also want to consider that Kesimpta (ofatumumab) is a self-administered subcutaneous injection that eliminates infusion logistics altogether, though it works through a somewhat different mechanism.